Dr. Nitzan Rosenfeld is a recognised expert in cell-free DNA analysis and its application for non-invasive cancer genomics. Originally trained in Physics, Dr. Rosenfeld specialised in quantitative molecular biology, obtaining a Ph.D. from the Weizmann Institute of Science under the supervision of Prof. Uri Alon. In 2005 he joined Rosetta Genomics, where he was Head of Computational Biology and led development of molecular tests that are in clinical use for oncology. Since 2009 he has been focusing on applications of circulating tumour DNA (ctDNA), as a group leader at the Cancer Research UK Cambridge Institute, University of Cambridge. His research group pioneered the use of Next-Generation Sequencing of ctDNA, demonstrating its potential as a liquid biopsy through a series of widely-cited publications describing whole exome, hybrid capture, and amplicon-based sequencing of ctDNA. Dr. Rosenfeld's work is funded by research grants from CRUK, ERC and others, and has been recognised by distinguished awards including the CRUK Future Leaders in Cancer Research prize (2013), the British Association for Cancer Research Translational Research Award (2013), the Foulkes Foundation Medal (2015), and the Meyenburg Cancer Research Award (2017). In 2014, Dr. Rosenfeld and colleagues founded Inivata, a global clinical cancer genomics company harnessing the potential of circulating DNA analysis to transform patient care. Its innovative InVision liquid biopsy platform is being employed by leading cancer institutes.